NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Terns Pharmaceuticals, Inc. (TERN) Stock Analysis

Terns Pharmaceuticals, Inc. (TERN) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

TERN

$52.95

$0.00 (0.00%)

Last trade May 15, 2026

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare TERN with… →

TERN Key Statistics

As of May 15, 2026
Trading
Open
$52.97
Previous Close
$52.95
52-Week Range
2.66–53.19
Volume
6.33M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
−0.38
Valuation
Market Cap
$6.12B
P/E Ratio
unprofitable
EPS (ttm)Profit attributable to each share over the last twelve months.
−1.03
Financials (FY)
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
1-Year Return
+1797.85%
Dividend and dates
Avg Volume
5.92M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

TERN Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+31.06%
2025+629.24%
2024 (partial year)−8.43%

As of May 15, 2026.

TERN Valuation vs Biotechnology Median

Median of 656 stocks
MetricTERNBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Terns Pharmaceuticals, Inc. (TERN) is capitalised at $6.12B on the latest close. The company sits in the Healthcare sector, in the Biotechnology industry. Headcount on file is 59.

Over the past 52 weeks the price has ranged from $2.66 to $53.19. The most recent close on file for TERN is $52.95, dated May 15, 2026. The close was unchanged from the previous session. The latest close sits 1,894.35% above that 52-week low.

Financial Health

Profit margin runs at 0%. Earnings per share on a trailing basis come to −1.03.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

The reported beta is −0.38. Daily returns over the trailing 1 year annualize to a volatility of 101.81%. The trailing one-year price return is +1,797.85%.

Growth & Income

No dividend is on file for TERN.

The record holds one complete calendar year, 2025, which returned +629.24%. 2026 is still running; the price is +31.06% year to date.

Peer Comparison

Terns Pharmaceuticals, Inc. (TERN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Terns Pharmaceuticals, Inc. TERN $6.12B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Terns Pharmaceuticals, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of May 15, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Terns Pharmaceuticals, Inc.

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1/2 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced metabolic stability and liver distribution that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-801 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California. As of May 4, 2026, Terns Pharmaceuticals, Inc. operates as a subsidiary of Merck Sharp & Dohme LLC.

Visit website →